PartnershipJul 13, 2026, 07:03 AM
Ocugen Signs OCU400 MENA Licensing Deal; Up to $255M Sales Milestones
AI Summary
Ocugen, Inc. announced a binding term sheet for a licensing agreement with Roots Pharmaceutical and Al-Dhow International Holding for exclusive rights to OCU400, its gene therapy for Retinitis Pigmentosa, in the Middle East and North Africa (MENA) region. Under the agreement, Ocugen is set to receive up to $4 million in upfront and near-term development milestone payments, along with up to $255 million in sales milestones and a 22% royalty on net sales. Ocugen will also manufacture and supply OCU400, expanding its reach into a region with high prevalence of RP.
Key Highlights
- Signed binding term sheet for exclusive OCU400 rights in MENA region.
- Partnered with Roots Pharmaceutical and Al-Dhow International Holding.
- Expected to receive up to $4 million in upfront and near-term milestones.
- Entitled to sales milestone payments up to $255 million.
- Will receive 22% royalty on net sales of OCU400.
- Ocugen to manufacture and supply commercial OCU400.
- Definitive agreement expected within 90 days.
- OCU400 Phase 3 topline readout expected 1Q 2027.
Price Impact
More from OCGN